MIRA PHARMACEUTICALS, INC. Logo

MIRA PHARMACEUTICALS, INC.

Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.

MIRA | US

Overview

Corporate Details

ISIN(s):
US60458C1045
LEI:
Country:
United States of America
Address:
1200 BRICKELL AVENUE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic and neuropsychiatric disorders. The company's pipeline is centered on two primary neuroscience programs. One program is developing Ketamir-2, a next-generation oral ketamine analog. The other is focused on a new molecular synthetic analog of THC (tetrahydrocannabinol). MIRA aims to address unmet medical needs by creating advanced, patent-protected treatment options for a range of central nervous system conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MIRA PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MIRA PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MIRA PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America NTRA
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330

Talk to a Data Expert

Have a question? We'll get back to you promptly.